Researchers, Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. from the Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. studied the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in men who have docetaxel-resistant hormone-refractory prostate cancer (HRPC). […]
The approval of Provenge has once again brought to the forefront the very important questions about the proper timing of treatments as well as the issue concerning how to combine therapies to maximize survival. We have, although there numbers are limited, different treatments that are used for the treatment of advanced prostate cancer, but we [...]
We all have been warned about the potential risk that hormone therapy (ADT) can cause to our heart and vascular health. A report from Lancet Oncology confirmed that men with prostate cancer living in Sweden when on hormonal therapies significantly increase their risk for experiencing a thromboembolic disease event. […]
Obesity has been associated with a worse prostate cancer prognosis and increased levels of insulin are thought to mediate this effect. It has been established that hyperinsulinemia associates with higher levels of insulin receptors (IR) in prostate cancers and increased tumor growth. Men with prostate cancer who are put on androgen blockade (ADT) develop increased [...]
As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]